Eastgate Biotech Profit Margin

Eastgate Biotech (ETBI) currently reports a profit margin of -9598.82% as of September 2017. That compares with -3057.29% in the prior-year period — down 214.0% year over year. That is below the sector sector average of 13.23%. Use the charts on this page to explore Eastgate Biotech's profit margin history and peer comparisons.

Eastgate Biotech's profit margin decreased from -3057.29% to -9598.82% — a 214.0% year-over-year decrease (period ending September 2017). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eastgate Biotech's profit margin of -9598.82% is lower than the its sector sector average of 13.23%. That is roughly 72674.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Eastgate Biotech's current -9598.82% should be judged against industry norms (sector average: 13.23%) and against ETBI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -9598.82%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.23%. From there, open related valuation or income-statement pages for Eastgate Biotech, and consider following ETBI for alerts when major investors trade the stock.